Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cormedix ( (CRMD) ) has shared an announcement.
On June 26, 2025, CorMedix Inc. announced an underwriting agreement with RBC Capital Markets for the sale of 6,604,507 shares of its common stock, with an option for underwriters to purchase additional shares. The offering closed on June 30, 2025, raising approximately $82.2 million, potentially increasing to $94.8 million if the option is fully exercised. The proceeds are intended for general corporate purposes, including working capital and research and development. This move is part of CorMedix’s strategy to strengthen its financial position and support its ongoing and future projects, potentially enhancing its market presence and operational capabilities.
The most recent analyst rating on (CRMD) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Neutral.
Cormedix’s overall stock score is influenced by a challenging financial position, marked by ongoing losses and negative cash flows. Despite technical indicators showing potential downward pressure, the recent earnings call provides a positive outlook with record-breaking revenue and strategic growth initiatives. However, valuation concerns and operational challenges remain significant obstacles.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The company is focused on commercializing its lead product DefenCath, which was approved by the FDA in November 2023. CorMedix launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. The company is also commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and intends to develop DefenCath as a catheter lock solution for other patient populations.
Average Trading Volume: 1,971,464
Technical Sentiment Signal: Strong Buy
Current Market Cap: $847.8M
For a thorough assessment of CRMD stock, go to TipRanks’ Stock Analysis page.